Scarica l'app Stockscreener
7.62
3.39%
0.24
Dopo l'orario di chiusura:
7.62
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - Bluefield Daily Telegraph
Is Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Niagen Bioscience Inc [NAGE] stock for 2,146 USD was acquired by Lopez Carlos Luis - knoxdaily.com
Is it possible to buy Niagen Bioscience Inc(NAGE) shares at a good price now? - uspostnews.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap up US$51m last week, benefiting both individual investors who own 36% as well as insiders - Yahoo Finance
Supplement Maker Rebrands - Los Angeles Business Journal
Robert Fried Exercises Options, Realizes $173KNiagen Bioscience (NASDAQ:NAGE) - Benzinga
Market Resilience: Niagen Bioscience Inc (NAGE) Finishes Weak at 5.42, Down -3.56 - DWinneX
Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs - marketscreener.com
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - Business Wire
Niagen Bioscience maintains stability amid tariffs By Investing.com - Investing.com South Africa
Niagen Bioscience Stands Firm Despite Global Tariff Concerns - Finimize
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments - MarketScreener
Niagen Bioscience maintains stability amid tariffs - Investing.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues - simplywall.st
Growth Companies With High Insider Ownership For April 2025 - Yahoo Finance
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - MarketScreener
H.C. Wainwright holds $11 target on Niagen Bioscience stock By Investing.com - Investing.com Canada
H.C. Wainwright holds $11 target on Niagen Bioscience stock - Investing.com
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE) - simplywall.st
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - MarketScreener
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results - MarketScreener
Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent - TipRanks
Niagen Bioscience secures new patent for NAD+ precursors - Investing.com
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire
Niagen Bioscience, Inc. Rings the Closing Bell - Nasdaq
ChromaDex Completes Name Change to Niagen Bioscience -March 19, 2025 at 09:29 am EDT - Marketscreener.com
Chromadex Rebrands to Niagen Bioscience, Inc. - TipRanks
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - The Bakersfield Californian
ChromaDex Corporation will Change its Ticker to NAGE from CDXC - marketscreener.com
ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal
Chromadex’s Strategic Rebranding and Promising Clinical Developments Justify Buy Rating - TipRanks
ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries - NutraIngredients-USA.com
ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - insights.citeline.com
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Bluefield Daily Telegraph
ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com
Healthy Aging Leader ChromaDex Takes Center Stage at ROTH Conference Longevity Panel - Stock Titan
ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High - Seeking Alpha
ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Call Transcript - Insider Monkey
When Will ChromaDex Reveal Its Q4 Performance? Key Date for NAD+ Leader's Financial Results - Stock Titan
ChromaDex to Present at Lytham Partners Healthcare Summit, Showcasing NAD+ Research Advances - StockTitan
Daré Bioscience, Inc. and ARPA-H Ring the Nasdaq Stock Market Closing Bell - Nasdaq
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire
Thorne acquires brain health formula partner in $5 million deal - SupplySide Supplement Journal
The proper role of pre-blends of nutrients in production of dietary supplements - SupplySide Supplement Journal
FDA Criminal Office Said to Be Examining Drug Ostarine in Dietary Supplements - SupplySide Supplement Journal
Technology disruption in the dietary supplement industry - SupplySide Supplement Journal
IV and Injection Offerings to Additional Leading Wellness Clinics - Business Wire
GMP Requirements for Softgels - SupplySide Supplement Journal
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions - Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 - Business Wire
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) - Business Wire
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen - Business Wire
Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable - simplywall.st
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024 - Business Wire
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award - Business Wire
(Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD - Business Wire
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):